Washington Health Innovation Council Third-Party Litigation Funding Report

Washington, D.C.—AdvaMed, the Medtech Association, asked the US District Court for the District of Massachusetts to rule as a matter of law that independent sales agent (ISA) arrangements do not — by themselves — violate the Anti-Kickback Statute (AKS) and, accordingly, grant summary judgment in the Langer v Zimmer Biomet case.

Christopher L. White, Esq., AdvaMed’s General Counsel & Chief Policy Officer, on why this year’s legal, compliance & regulatory programming is mission-critical as medtech leaders navigate uncertainty, shifting enforcement priorities, and a rapidly changing global legal landscape.

Washington, DC.—AdvaMed, the medtech association, asked the Court of Appeals for the Third Circuit to vacate the judgment of the District Court, which if allowed to stand, would have significant and deleterious effects on patient care.

AdvaMed submitted public comments in response to HHS’s request for information on eliminating federal regulations that hinder economic growth, innovation, and American competitiveness.

AdvaMed calls for federal privacy laws that reflect how medical devices use patient data differently from consumer health tools.

A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.